Acute toxicity is a dose-limiting factor for intravenous polymyxin B: A safety and pharmacokinetic study in healthy Chinese subjects-Reference-Cited by-同舟云学术

Acute toxicity is a dose-limiting factor for intravenous polymyxin B: A safety and pharmacokinetic study in healthy Chinese subjects

Published:2021-02 Issue:2 Volume:82 Page:207-215
ISSN:0163-4453
Container-title:Journal of Infection
language:en
Short-container-title:Journal of Infection

Author:

Liu Xiaofen,Chen Yuancheng,Yang Haijing,Li Jian,Yu Jicheng,Yu Zhenwei,Cao Guoying,Wu Xiaojie,Wang Yu,Wu Hailan,Fan Yaxin,Wang Jingjing,Wu Jufang,Jin Yi,Guo Beining,Hu Jiali,Bian Xingchen,Li Xin,Zhang Jing

Funder

Ministry of Science and Technology of the People's Republic of China

Science and Technology Commission of Shanghai Municipality

National Natural Science Foundation of China

Publisher

Elsevier BV

Subject

Infectious Diseases,Microbiology (medical)

Reference39 articles.

1. Multidrug-resistant gram-negative bacterial infections in the hospital setting: overview, implications for clinical practice, and emerging treatment options;Cerceo;Microbial Drug Resist,2016

2. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections;Falagas;Clin Infec Dis,2005

3. Polymyxin B versus colistin: an update;Cai;Exp Rev Anti Infect Ther,2015

4. Comparative pharmacokinetic profiling of different polymyxin B components;Manchandani;Antimicrob Agents Chemother,2016

5. International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti‐infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP)

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Outcome of intravenous and inhaled polymyxin B treatment in patients with multidrug-resistant gram-negative bacterial pneumonia;International Journal of Antimicrobial Agents;2024-10

2. Transmission Dynamics and Novel Treatments of High Risk Carbapenem-Resistant Klebsiella pneumoniae: The Lens of One Health;Pharmaceuticals;2024-09-12

3. Evaluating nephrotoxicity reduction in a novel polymyxin B formulation: insights from a 3D kidney-on-a-chip model;Antimicrobial Agents and Chemotherapy;2024-09-03

4. Factors affecting the effectiveness and safety of polymyxin B in the treatment of Gram-negative bacterial infections: A meta-analysis of 96 articles;International Journal of Antimicrobial Agents;2024-09

5. Pharmacokinetics and safety of colistin sulfate after single and multiple intravenous doses in healthy Chinese subjects;International Journal of Antimicrobial Agents;2024-09